ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

ANAC Anacor Pharmaceuticals, Inc.

99.20
0.00 (0.00%)
24 Jan 2025 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Anacor Pharmaceuticals, Inc. NASDAQ:ANAC NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 99.20 0.01 99.25 0 00:00:00

ANACOR SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces the Investigation of Anacor Pharmaceuticals, Inc. (ANAC) Over the P...

20/05/2016 7:08pm

Business Wire


Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC)
Historical Stock Chart


From Jan 2020 to Jan 2025

Click Here for more Anacor Pharmaceuticals, Inc. Charts.

Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Anacor Pharmaceuticals, Inc. (“Anacor” or the “Company”) (Nasdaq:ANAC) for potential breaches of fiduciary duties in connection with the sale of the Company to Pfizer Inc. for approximately $5.2 billion.

The Company’s stockholders will only receive $99.25 in cash for each share of Anacor common stock they own. However, the offer is below at least one analyst’s price target of $130 per share and Anacor’s 52-week high of $156.93 per share.

Click here for more information: www.faruqilaw.com/ANAC. There is no cost or obligation to you.

The investigation focuses on whether Anacor’s Board of Directors breached their fiduciary duties to the Company’s stockholders by failing to conduct a fair sales process and whether and by how much this proposed transaction undervalues the Company to the detriment of Anacor’s shareholders.

Faruqi & Faruqi, LLP is a national law firm which represents investors and individuals in class action litigation. The firm is focused on providing exemplary legal services in complex litigation in the areas of securities, shareholder, antitrust and consumer litigation, throughout all phases of litigation. The firm has an experienced trial team which has achieved significant victories on behalf of the firm’s clients. To keep track of the latest securities litigation news, follow us on Twitter at www.twitter.com/MergerActivity or on Facebook at www.facebook.com/FaruqiLaw.

If you own common stock in Anacor and wish to obtain additional information and protect your investments free of charge, please visit us at www.faruqilaw.com/ANAC or contact Juan Monteverde, Esq. either via e-mail at jmonteverde@faruqilaw.com or by telephone at (877) 247-4292 or (212) 983-9330.

Attorney Advertising. (C) 2016 Faruqi & Faruqi, LLP. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We are happy to discuss your particular case.

Faruqi & Faruqi, LLPJuan Monteverde, Esq.212-983-9330Toll Free: 877-247-4292jmonteverde@faruqilaw.com

1 Year Anacor Pharmaceuticals, Inc. Chart

1 Year Anacor Pharmaceuticals, Inc. Chart

1 Month Anacor Pharmaceuticals, Inc. Chart

1 Month Anacor Pharmaceuticals, Inc. Chart

Your Recent History

Delayed Upgrade Clock